Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, MD PhD, Zsolt Nagy, MD PhD, Szabolcs Kosztolányi, MD, Árpád Szomor, MD PhD, Tamás Schneider, MD PhD, Beáta Deák, MD PhD, Krisztina Wolf, MD, Márk Plander, MD PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, MD PhD, Árpád Bátai, MD, Mónika Pető, MD, János Fábián, MD, Tamas Masszi, MD PhD, Gabor Mikala, MD PhD

Blood (2017) 130 (Supplement 1): 1865.

https://doi.org/10.1182/blood.V130.Suppl_1.1865.1865

Published: 2017

Journal Articles

Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan

Nicole M.A. Blijlevens, MD, PhD, Maarten E de Chateau, MD, PhD, Gergely Krivan, MD, Werner Rabitsch, MD, Arpad Szomor, MD, Robert Pytlik, MD, Agneta Lissmats, PhD, Hans Erik Johnsen, MD, Tapani Ruutu, MD, Hermann Einsele, MD, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 904.

https://doi.org/10.1182/blood.V116.21.904.904

Published: 2010

Journal Articles

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .

Andres JM Ferreri, MD, Silvia Govi, M.D., Giuseppina Patrizia Dognini, M.D., Maria Bouzani, M.D., Claudia Ruth Bollinguer, M.D., Michel D’Incan, M.D., Emmanuel Delaporte, M.D., Mehdi Hamadani, M.D., Fabrice Jardin, M.D., Magdalena Martusewicz-Boros, M.D., Mauro Montanari, M.D., Arpad Szomor, M.D., Roberto Crocchiolo, M.D., Emanuele Zucca, M.D., Franco Cavalli, M.D., Maurilio Ponzoni, M.D.

Blood (2008) 112 (11): 2008.

https://doi.org/10.1182/blood.V112.11.2008.2008

Published: 2008

Journal Articles

Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.

Hajna Losonczy, MD, PhD, Agnes Nagy, MD, Orsolya Toth, MD, Katalin Balassa, MD, Marianna David, MD, PhD, Marianna Kecskes, MD, Timea Vidra, MD, Arpad Szomor, MD, PhD

Blood (2005) 106 (11): 1632.

https://doi.org/10.1182/blood.V106.11.1632.1632

Published: 2005

NARROW

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .

Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.

Email alerts

ASH Publications

American Society of Hematology

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .

Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only